NervGen Pharma Appoints Neil Klompas to Board of Directors
Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company’s mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a study Vancouver, Canada, July 22, 2024 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the […]
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, Canada June 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the […]
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
Vancouver, Canada, June 20, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2nd Annual Spinal Cord Injury Investor Symposium (“2nd SCIIS”), presented […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. June 6, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company exercisable at a price of $1.79 per share (the […]
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Glenn Ives appointed as Chair of the Board John Ruffolo appointed as Chair of the Audit Committee Vancouver, Canada, June 5, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, […]
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, Canada, May 17, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51st Annual Scientific […]
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, Canada, May 16, 2024 – NervGen […]
NervGen Files Management Information Circular and Announces Board of Directors Transition
Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen’s Board of Directors Annual General Meeting of Shareholders to be held on June 4, 2024 Vancouver, Canada, May 7, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical-stage biotech company dedicated to […]
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, Canada, April 25, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC (“Russo Partners”), a New York based full-service strategic communications firm to provide media […]
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury Vancouver, Canada April 17, […]